Anne Barlier researcher
Barlier, Anne, 1963-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Barlier, Anne
VIAF ID: 202304475 ( Personal )
Permalink: http://viaf.org/viaf/202304475
Preferred Forms
-
100 0 _
‡a
Anne Barlier
‡c
researcher
-
100 1 _
‡a
Barlier, Anne
-
100 1 _
‡a
Barlier, Anne,
‡d
1963-....
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| Altérations des mécanismes de transduction et étoipathogénie des adénomes somatotropes humains |
|
| The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. |
|
| Case Report of GNAS Epigenetic Defect Revealed by a Congenital Hypothyroidism |
|
| Une cause de calcifications intracérébrales à connaître : la pseudohypoparathyroïdie de type Ib |
|
| Cervical paragangliomas: is SDH genetic analysis systematically required? |
|
| Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. |
|
| Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities |
|
| Conditional overexpression of the wild-type Gs alpha as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines |
|
| Contribution of high throughput sequencing associated to unique molecular identifiers in the management of pituitary gland tumours. |
|
| Corrélation génotype-phénotype sur une série de 83 méningiomes : intérêt clinique ? |
|
| Deciphering full omics of pituitary tumors : classification, diagnostic and pronostic. |
|
| Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections. |
|
| Defining novel mechanisms of tumor progression and novel therapeutic targets for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). |
|
| Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. |
|
| Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency. |
|
| Dose-dependent dual role of PIT-1 (POU1F1) in somatolactotroph cell proliferation and apoptosis |
|
| Etiologies héréditaires et somatiques des adénomes hypophysaires : étude du gène Men1 et du locus Gnas |
|
| Étiologies moléculaires des insuffisances surrénales primaires congénitales : développements statistiques pour la validation du séquençage parallèle massif |
|
| Etude d'un locus soumis à empreinte parentale : le locus GNAS. Rôle des transcrits et maintien de l'empreinte |
|
| European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: an EQA study |
|
| Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial |
|
| Expression of functional growth hormone secretagogue receptors in human pituitary adenomas: polymerase chain reaction, triple in-situ hybridization and cell culture studies. |
|
| Frequent Large GermlineHRPT2Deletions in a French National Cohort of Patients With Primary Hyperparathyroidism |
|
| Gene therapy of human pituitary adenomas in vitro : Evaluation of the role of somatostatinergic receptor sst2 and of a dominant negative of the transcription factor Pitx2. |
|
| A genome-wide approach reveals novel imprinted genes expressed in the human placenta |
|
| Genomic alterations in pituitary tumors : identification of candidate genes associated with tumorigenesis and prognosis. |
|
| Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs. |
|
| GNAS et empreinte parentale : Caractérisation des GNAS-miRNAs et d'une nouvelle DMR |
|
| Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. |
|
| The gsp oncogene disrupts Ras/ERK-dependent prolactin gene regulation in gsp inducible somatotroph cell line. |
|
| Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency |
|
| High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. |
|
| Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’étude des Tumeurs Endocrines (GTE) cohort study |
|
| Identification de nouveaux gènes de prédisposition aux parangangliomes |
|
| Identification of new paraganglioma susceptibility genes. |
|
| Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue |
|
| In vivo and in vitro evidence of somatostatin receptors expression in a dedifferentiated retroperitoneal liposarcoma |
|
| INTERET DU RAPPORT MOLAIRE DES GONADOTROPHINES (ALPHA, FSH, LH) AU DIAGNOSTIC DES ADENOMES GONADOTROPES |
|
| Lessons from monogenic causes of growth hormone deficiency. |
|
| Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment |
|
| Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. |
|
| MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency |
|
| Médecine moléculaire |
|
| Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives |
|
| Méthodes d'analyse de la méthylation du locus GNAS et classification des pseudohypoparathroïdies |
|
| Molecular characterization of metastatic medullary thyroid carcinomas. |
|
| The molecular pathogenesis of GIP-dependent adrenal hyperplasia and invasive pituitary adenomas. |
|
| Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. |
|
| New regulatory mechanisms in the growth of endocrine tumors : digestive neuroendocrine tumors, pitiutary adenomas |
|
| New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro. |
|
| Nouveaux mécanismes de régulation de la croissance des tumeurs endocrines : tumeurs neuroendocrines digestives, adénomes hypophysaires. |
|
| Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro |
|
| Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures |
|
| Pathogénie moléculaire de l'hyperplasie surrénalienne GIP-dépendante et du comportement invasif des adénomes hypophysaires |
|
| Phenotypic Homogeneity and Genotypic Variability in a Large Series of Congenital Isolated ACTH-Deficiency Patients withTPITGene Mutations |
|
| Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas). |
|
| Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. |
|
| Pituitary hormone deficiencies due to transcription factor gene alterations. |
|
| Place du séquençage haut débit dans la prise en charge des méningiomes humains |
|
| Preoperative 18F-FDG Uptake is Strongly Correlated with Malignancy, Weiss Score, and Molecular Markers of Aggressiveness in Adrenal Cortical Tumors |
|
| Primary hyperparathyroidism as first manifestation in MEN 2A: an international multicenter study |
|
| PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. |
|
| Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. |
|
| Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. |
|
| Quelles causes génétiques rechercher en présence d’un déficit en hormone de croissance ? |
|
| RET gene mutations are not involved in the origin of human testicular seminoma. |
|
| The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. |
|
| Role of AIP (Aryl Hydrocarbon Receptor Interacting Protein) in Pituitary Adenoma Tumorigenesis. |
|
| Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases. |
|
| The significance of MEN1 mutations in pituitary carcinomas. |
|
| Simultaneous hyper- and hypomethylation at imprinted loci in a subset of patients with GNAS epimutations underlies a complex and different mechanism of multilocus methylation defect in pseudohypoparathyroidism type 1b. |
|
| Sinonasal paraganglioma with long-delayed recurrence and metastases: genetic and imaging findings. |
|
| Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. |
|
| Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. |
|
| Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. |
|
| Study of a Human Imprinted Locus : the GNAS Locus. Role of the GNAS Transcripts and Imprinting Maintenance. |
|
| Targeting Dopamine Receptors Subtype 2 (D2DR) in Pheochromocytomas: Head-to-Head Comparison Between In Vitro and In Vivo Findings |
|
| Thérapies alternatives des adénomes somatotropes et lactotropes résistants : implication du facteur de transcription POU1F1 et du récepteur SST2 |
|
| Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report. |
|
| Unusual presentation of multiple endocrine neoplasia type 2A in a patient with the C634R mutation of the RET-protooncogene |
|
